Gate Booster 第 4 期:發帖瓜分 1,500 $USDT
🔹 發布 TradFi 黃金福袋原創內容,可得 15 $USDT,名額有限先到先得
🔹 本期支持 X、YouTube 發布原創內容
🔹 無需複雜操作,流程清晰透明
🔹 流程:申請成為 Booster → 領取任務 → 發布原創內容 → 回鏈登記 → 等待審核及發獎
📅 任務截止時間:03月20日16:00(UTC+8)
立即領取任務:https://www.gate.com/booster/10028?pid=allPort&ch=KTag1BmC
更多詳情:https://www.gate.com/announcements/article/50203
3 No-Brainer Warren Buffett Stocks to Buy Right Now
Warren Buffett, often called the greatest investor of all time, stepped down as chairman and CEO of Berkshire Hathaway in December 2025. Yet while Greg Abel, Buffett’s successor, is now at the helm of the Omaha, Nebraska-based holding company, he isn’t looking to rock the boat.
As discussed in his recently released 18-page letter to shareholders, Abel has committed to maintaining Berkshire’s decentralized structure. He also noted how he doesn’t intend to make many changes to the key holdings in Berkshire’s equity portfolio. Abel may have been talking mainly about Berkshire’s positions in American Express and Coca-Cola, but he may have similar thoughts about the following Warren Buffett stocks, all of which have solid long-term potential: Chevron (CVX +0.00%), Domino’s Pizza (DPZ +1.94%), and DaVita (DVA 1.53%).
Image source: The Motley Fool.
Rising oil prices bolster the Chevron bull case
Berkshire Hathaway holds a 6.5% stake in Chevron. At current prices, this position in the oil and gas giant is worth around $24.7 billion.
Expand
NYSE: CVX
Chevron
Today’s Change
(0.00%) $0.00
Current Price
$196.97
Key Data Points
Market Cap
$393B
Day’s Range
$194.71 - $197.62
52wk Range
$132.04 - $198.88
Volume
449K
Avg Vol
12M
Gross Margin
14.66%
Dividend Yield
3.51%
Chevron shares have soared nearly 25% amid the recent run-up in energy prices. But even when crude oil prices were languishing several months ago, one could already make a strong bull case for the stock.
That’s because Chevron’s game plan of increasing production and lowering operating costs pointed to a big earnings rebound. However, with oil prices surging and likely to stay elevated as conflict in the Middle East persists, these improvements could be even more dramatic. In the years ahead, the positive impact of Chevron’s turnaround could add to these gains.
Domino’s could soon command a princely premium to peers
Domino’s currently trades for around 21 times forward earnings. That’s on the higher end of the valuation range among fast-food stocks. However, given the company’s particular strengths, shares could eventually trade at an even higher valuation.
Expand
NASDAQ: DPZ
Domino’s Pizza
Today’s Change
(1.94%) $7.63
Current Price
$401.63
Key Data Points
Market Cap
$13B
Day’s Range
$394.71 - $403.48
52wk Range
$370.70 - $499.08
Volume
983K
Avg Vol
827K
Gross Margin
39.95%
Dividend Yield
1.76%
As BTIG analyst Peter Selah recently noted, in a reiterated “buy” rating of the stock, Domino’s continues to generate positive same-store sales growth, while competitors like Yum! Brands’ Pizza Hut unit and Papa John’s have experienced declining same-store sales.
If this strong performance persists and gets noticed by investors, Domino’s shares could move up to a valuation on par with Yum! Brands and McDonald’s. Both stocks currently trade at forward multiples in the mid-20s. A moderate valuation boost, coupled with steady earnings growth, could turn Domino’s into a long-term compounder.
DaVita is the dark horse contender among Warren Buffett stocks
Among the many stocks Berkshire Hathaway owns, DaVita gets too little attention and appreciation. Perhaps it has to do with how DaVita’s main business, operating kidney dialysis centers, has performed.
Expand
NYSE: DVA
DaVita
Today’s Change
(-1.53%) $-2.34
Current Price
$150.72
Key Data Points
Market Cap
$10B
Day’s Range
$146.09 - $153.77
52wk Range
$101.00 - $159.42
Volume
1.3M
Avg Vol
1.1M
Gross Margin
27.00%
DaVita has struggled with flat customer volumes and rising costs. Yet, while full-year earnings declined 11.7% last year, a quiet recovery could be taking shape.
Results for the fourth quarter came in well ahead of Wall Street estimates. Management also provided promising guidance for 2026, including estimated adjusted earnings of between $13.60 and $15 per share. With this, DaVita could be trading for as low as 10 times forward earnings right now.
Long term, if there’s an earnings growth resurgence or if DaVita further diversifies its kidney care offerings, climbing to a higher forward multiple could be within reach.